文献速递胸部肿瘤

MET扩增通过抑制STING削弱肺癌免疫治疗应答

MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING.
PubMed 文献 · Cancer Discov · 2021-06-07

该研究分析81例接受免疫检查点阻断(ICB)治疗的肺癌患者,发现MET扩增者ICB耐药且无进展生存期差。MET扩增肿瘤STING水平及抗肿瘤T细胞浸润显著降低,单细胞RNA测序揭示免疫抑制特征;机制上MET信号经UPF1调控STING 3'-UTR长度下调STING,抑制MET可克服耐药。

要点

  • MET扩增肺癌患者对ICB耐药且无进展生存期差。
  • MET扩增肿瘤STING水平与抗肿瘤T细胞浸润显著降低。
  • 抑制MET可克服MET扩增所致ICB耐药,支持联合治疗。

核心结论

  • MET扩增通过抑制STING削弱肺癌对ICB的应答,抑制MET可克服该耐药。
  • 建议MET抑制剂联合ICB用于原发MET扩增或EGFR-TKI耐药相关MET扩增患者。

研究设计与样本

  • 研究纳入81例接受ICB治疗的肺癌患者进行分析。
  • 对超过20,000个单免疫细胞进行深度单细胞RNA测序。

主要发现

  • MET扩增患者对ICB耐药且无进展生存期差。
  • MET扩增肿瘤STING水平及抗肿瘤T细胞浸润显著降低。
  • MET扩增患者中XIST与CD96阳性耗竭NK细胞亚群增加,CD8+ T细胞与NK细胞群体减少。
  • 致癌MET信号诱导UPF1磷酸化,通过UPF1调控STING的3'-UTR长度下调肿瘤细胞STING表达。

临床怎么用

  • 对拟接受ICB的肺癌患者应评估MET扩增状态以预判耐药。
  • MET扩增患者可考虑MET抑制剂联合ICB以克服耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint blockade (ICB) has revolutionized cancer therapy. However, the response of patients to ICB is difficult to predict. Here, we examined 81 patients with lung cancer under ICB treatment and found that patients with MET amplification were resistant to ICB and had a poor progression-free survival. Tumors with MET amplifications had significantly decreased STING levels and antitumor T-cell infiltration. Furthermore, we performed deep single-cell RNA sequencing on more than 20,000 single immune cells and identified an immunosuppressive signature with increased subsets of XIST- and CD96-positive exhausted natural killer (NK) cells and decreased CD8+ T-cell and NK-cell populations in patients with MET amplification. Mechanistically, we found that oncogenic MET signaling induces phosphorylation of UPF1 and downregulates tumor cell STING expression via modulation of the 3'-UTR length of STING by UPF1. Decreased efficiency of ICB by MET amplification can be overcome by inhibiting MET. SIGNIFICANCE: We suggest that the combination of MET inhibitor together with ICB will overcome ICB resistance induced by MET amplification. Our report reveals much-needed information that will benefit the treatment of patients with primary MET amplification or EGFR-tyrosine kinase inhibitor resistant-related MET amplification.This article is highlighted in the In This Issue feature, p. 2659.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Yang Q, Zeng X, et al. MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING. Cancer Discov. 2021. PMID: 34099454. doi:10.1158/2159-8290.CD-20-1500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。